Publications | R2M Pharma

top of page

Aberrant TRIM7 expression potentiates RACO-1 mediated proliferation and dysregulated interferon responsiveness in the setting of anti-PD-1 acquired resistance in cancer

American Association for Cancer Research

Presented at AACR24, San Diego

April 9, 2024

Novel series of tunable µOR modulators with enhanced brain penetration for the treatment of opioid use disorder, pain and neuropsychiatric indications

Bioorganic & Medicinal Chemistry Letters

Volume 92

August 15, 2023

EPD1504: a novel μ-opioid receptor partial agonist attenuates obsessive–compulsive disorder (OCD)-like behaviors

Frontiers in Psychiatry

Volume 14 - 2023

June 30, 2023

Phenotypic Screening with Deep Learning Identifies HDAC6 Inhibitors As Cardioprotective in a BAG3 Mouse Model of Dilated Cardiomyopathy

Science Translational Medicine

Volume 14, Issue 652

July 6, 2022

A Novel Maintenance Therapeutic for Opioid Use Disorder

The Journal of Pharmacology and Experimental Therapeutics

Volume 368, Issue 2

August 1, 2021

Phenotypic Screening Identifies HDAC6 Inhibitors as Cardioprotective Agents

2021 European Society of Cardiology - Heart Failure Congress

July 29, 2021

Optimization of Novel μOR Ligands for Enhanced CNS Penetration

Presented at the ACS Fall 2020 Virtual Meeting & Expo

August 17-20, 2020

Control of the μ-Opioid Receptor Efficacy In Vitro and In Vivo by Novel Conformationally Restricted Cyclopropane Carboxamide-derived Cis/Trans Isomers

Presented at the ACS Fall 2020 Virtual Meeting & Expo

August 17-20, 2020

Novel Partial Mu Opioid Agonists for the Treatment of Opioid Use Disorder

Presented at the NIH HEAL Investigators Meeting

January 16-17, 2020

bottom of page